Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

Repligen Corporation

RGENNASDAQEQUITYCurrent

Annual Report

Filed Mar 14, 2025Accepted Mar 13, 2025, 7:14 PM EDTCIK 730272Accession 0000950170-25-038999
Share

Company context

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Current securities

Recent company filings

  1. 4 filingSep 22, 2026
  2. 144 filingSep 21, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 15, 2026
  4. 425 filingSep 8, 2026
  5. Other EventsSep 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗